MCL
Advertisement
This week on DocWire, we covered the latest breaking research from the American Society of Hematology (ASH) 2021 Annual ...
At the 2021 American Society of Hematology (ASH) Annual Meeting, researchers presented long-term follow-up data from a ...
According to updated data from the phase I/II BRUIN study, presented at the 2021 American Society of Hematology Annual ...
Following its FDA approval in 2020 based on results from the ZUMA-2 trial, brexucabtagene autoleucel (brexu-cel) has ...
Each week on DocWire News, editors bring you the latest in oncology news and cancer research. In case you missed it, ...
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
In the phase II CITADEL-205 study, roughly two-thirds of patients with relapsed/refractory and Bruton tyrosine kinase ...
A recent study of KTE-X19 (also known as brexucabtagene autoleucel) supports the use of chimeric antigen receptor (CAR) ...
Five-year follow-up data from the phase III MCL Younger trial found a sustained benefit associated with high-dose ...
Patients with mantle cell lymphoma who are unmarried, have a lower educational level, or with multiple comorbidities are ...
In younger patients with mantle cell lymphoma (MCL), pre-transplant MRD status in both bone marrow and peripheral blood ...
A study has found that the addition of rituximab to ixazomib, when used as maintenance therapy following autologous ...
Highly selective and irreversible Bruton’s tyrosine kinase inhibitor orelabrutinib was associated with continuous ...
Parsaclisib was clinically active in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who were ...
Final results from the Nordic Lymphoma Group’s phase II PHILEMON trial showed that a combination of ibrutinib, ...
Venetoclax, Lenalidomide, and Rituximab Combo Is Well Tolerated, Shows Promising Efficacy in R/R MCL
A combination treatment approach consisting of venetoclax, lenalidomide, and rituximab was well tolerated and ...
The U.S. Food and Drug Administration (FDA) approved Brukinsa™ (zanubrutinib) capsules for the treatment of adults ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.